Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 4

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Ovarian Neoplasms 16Endometrial Neoplasms 16Breast Neoplasms 16Triple Negative Breast Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 14Lung Neoplasms 13Fallopian Tube Neoplasms 12Squamous Cell Carcinoma of Head and Neck 9Neoplasm Metastasis 7Carcinoma 5Stomach Neoplasms 4Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Peritoneal Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Esophageal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Respiratory Tract Neoplasms 2Pathologic Complete Response 2Melanoma 2Lung Diseases 2Hypopharyngeal Neoplasms 2

Interventions

pembrolizumab 17Bevacizumab 12Standard of Care 10Cyclophosphamide 9Carboplatin 9Doxorubicin 7Cetuximab 7Nivolumab 6Exercise 6olaparib 5atezolizumab 5Rituximab 5Radiotherapy 5Pemetrexed 5Fluorouracil 5Cisplatin 5durvalumab 4dostarlimab 4abemaciclib 4Temozolomide 4Prednisone 4Paclitaxel 4Leucovorin 4Blood Specimen Collection 4venetoclax 3temsirolimus 3talazoparib 3pertuzumab 3obinutuzumab 3ibrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × Paclitaxel × 30 days × Clear all
NCT05256225 2026-05-27

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

NCT04449549 2026-05-22

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
82 enrolled
Tumor-Agnostic

Neoplasms

NCT05954312 2026-05-08

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Vividion Therapeutics, Inc.

Phase 1 Recruiting
290 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡